The chronic hepatitis D virus market is expected to grow steadily, driven by a relatively small pipeline of emerging therapies. Leading candidates, such as Brelovitug from Bluejay Therapeutics and the ...
New Scientist on MSN
This virus infects most of us – but why do only some get very ill?
The ubiquitous Epstein-Barr virus is increasingly being linked to conditions like multiple sclerosis and lupus. But why do ...
Morning Overview on MSN
This common virus hits almost everyone, but why do only a few get crushed?
The common cold is so ubiquitous that it feels like background noise, yet for a subset of people it is a wrecking ball that ...
If you are dealing with a chronic illness, being vaccinated against other diseases becomes much more important.
Aligos Therapeutics is a clinical-stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases. The company is dedicated to educating ...
People who have had COVID-19 are more likely to develop chronic fatigue syndrome, officially known as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). That’s according to a study published ...
Huahei Health has won the first approval in China for a drug to treat chronic infections with hepatitis D virus (HDV), ...
The immune system’s reaction to the common Epstein-Barr virus can ultimately damage the brain and contribute to multiple sclerosis (MS). This is shown by new research from Karolinska Institutet, ...
A study published in Nature looks at genetic determinants of persistent Epstein-Barr virus DNA and associations with chronic conditions. Prof Lawrence Young, Virologist and Emeritus Professor of ...
Nearly all adults carry Epstein–Barr virus—but new research reveals how it can hijack immune cells, sparking a chronic disease that attacks the body from within. This colorized transmission electron ...
In the most rigorous trial to date, oral silymarin was not superior to placebo in decreasing disease activity. Silymarin is a botanical extract of milk thistle commonly used by patients with liver ...
The chronic hepatitis D virus market is expected to grow steadily, driven by a relatively small pipeline of emerging therapies. Leading candidates, such as Brelovitug from Bluejay Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results